Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.53 |
| ▸ | CNR1 | P21554 | 8/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432161 | 0.93 | CNR2 (0.62) | CNR2CNR1RIPK1POLBGAA | |
| SCHEMBL4935120 | 0.93 | CNR2 (0.62) | CNR2CNR1RIPK1POLBGAA | |
| SCHEMBL4924777 | 0.93 | CNR2 (0.62) | CNR2CNR1RIPK1POLBGAA | |
| SCHEMBL4924616 | 0.88 | CNR2 (0.53) | CNR2CNR1RIPK1MEN1KMT2A | |
| SCHEMBL4930729 | 0.88 | CNR2 (0.64) | CNR2CNR1RIPK1MEN1KMT2A | |
| SCHEMBL4934781 | 0.86 | CNR2 (0.54) | CNR2CNR1RIPK1MAPTCRACR2A | |
| SCHEMBL4934275 | 0.83 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL4931773 | 0.83 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL4936768 | 0.83 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL4933934 | 0.83 | CNR2 (0.63) | CNR2CNR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885RIPK1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.